509 related articles for article (PubMed ID: 29386018)
1. Targeting Gas6/TAM in cancer cells and tumor microenvironment.
Wu G; Ma Z; Cheng Y; Hu W; Deng C; Jiang S; Li T; Chen F; Yang Y
Mol Cancer; 2018 Jan; 17(1):20. PubMed ID: 29386018
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
[TBL] [Abstract][Full Text] [Related]
3. TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.
Schmitz R; Valls AF; Yerbes R; von Richter S; Kahlert C; Loges S; Weitz J; Schneider M; Ruiz de Almodovar C; Ulrich A; Schmidt T
Oncotarget; 2016 Aug; 7(35):56355-56370. PubMed ID: 27486820
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
Tanaka M; Siemann DW
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576116
[TBL] [Abstract][Full Text] [Related]
5. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Peeters MJW; Rahbech A; Thor Straten P
Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
[TBL] [Abstract][Full Text] [Related]
6. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV; Amend SR; Pienta KJ
Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
[TBL] [Abstract][Full Text] [Related]
7. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
8. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
9. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights of Gas6/TAM in cancer development and therapy.
Wu G; Ma Z; Hu W; Wang D; Gong B; Fan C; Jiang S; Li T; Gao J; Yang Y
Cell Death Dis; 2017 Mar; 8(3):e2700. PubMed ID: 28333143
[TBL] [Abstract][Full Text] [Related]
11. The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion.
Zdżalik-Bielecka D; Poświata A; Kozik K; Jastrzębski K; Schink KO; Brewińska-Olchowik M; Piwocka K; Stenmark H; Miączyńska M
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244439
[TBL] [Abstract][Full Text] [Related]
12. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.
Waizenegger JS; Ben-Batalla I; Weinhold N; Meissner T; Wroblewski M; Janning M; Riecken K; Binder M; Atanackovic D; Taipaleenmaeki H; Schewe D; Sawall S; Gensch V; Cubas-Cordova M; Seckinger A; Fiedler W; Hesse E; Kröger N; Fehse B; Hose D; Klein B; Raab MS; Pantel K; Bokemeyer C; Loges S
Leukemia; 2015 Mar; 29(3):696-704. PubMed ID: 25102945
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
Kasikara C; Kumar S; Kimani S; Tsou WI; Geng K; Davra V; Sriram G; Devoe C; Nguyen KN; Antes A; Krantz A; Rymarczyk G; Wilczynski A; Empig C; Freimark B; Gray M; Schlunegger K; Hutchins J; Kotenko SV; Birge RB
Mol Cancer Res; 2017 Jun; 15(6):753-764. PubMed ID: 28184013
[TBL] [Abstract][Full Text] [Related]
14. Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation.
Pilli VS; Datta A; Dorsey A; Liu B; Majumder R
Oncol Rep; 2020 Oct; 44(4):1322-1332. PubMed ID: 32945517
[TBL] [Abstract][Full Text] [Related]
15. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration.
Duan Y; Luo L; Qiao C; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Scand J Immunol; 2019 Aug; 90(2):e12777. PubMed ID: 31075180
[TBL] [Abstract][Full Text] [Related]
16. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
Elife; 2014 Sep; 3():. PubMed ID: 25265470
[TBL] [Abstract][Full Text] [Related]
17. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance.
Baumann C; Ullrich A; Torka R
Mol Oncol; 2017 Oct; 11(10):1430-1447. PubMed ID: 28675785
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates with Gas6 in established multiple sclerosis lesions.
Weinger JG; Omari KM; Marsden K; Raine CS; Shafit-Zagardo B
Am J Pathol; 2009 Jul; 175(1):283-93. PubMed ID: 19541935
[TBL] [Abstract][Full Text] [Related]
19. Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination.
Binder MD; Cate HS; Prieto AL; Kemper D; Butzkueven H; Gresle MM; Cipriani T; Jokubaitis VG; Carmeliet P; Kilpatrick TJ
J Neurosci; 2008 May; 28(20):5195-206. PubMed ID: 18480276
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]